GIPR Binding Protein and GLP-1 Agonist for Sustained Metabolic Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for metabolic disorders such as type 2 diabetes, obesity, and non-alcoholic fatty liver disease are inadequate in providing sustained benefits, as they do not effectively target the GIP receptor (GIPR) and GLP-1 receptor pathways, leading to incomplete management of glucose and insulin levels.
Innovation Solution
Administering a combination of a GLP-1 receptor agonist and a GIPR antagonist, which can be administered separately or synergistically, to specifically bind to the GIPR, thereby modulating glucose and insulin metabolism, reducing body weight, and improving metabolic parameters.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for metabolic disorders are used, then some symptomatic relief is achieved, but sustained benefits are not provided and incomplete management of glucose and insulin levels occurs
Solution Approach 1:
The patent combines a GLP-1 receptor agonist with a GIPR antagonist into a single combination therapy formulation. This merging of two pharmacological agents targeting different receptors (GLP-1R and GIPR) allows simultaneous modulation of multiple incretin pathways, providing comprehensive management of glucose and insulin levels while maintaining sustained therapeutic benefits throughout the dosing period.
2Adaptability or versatility
If monotherapy with single pathway inhibitors is used, then treatment simplicity is maintained, but comprehensive metabolic management is insufficient
Solution Approach 1:
The combination therapy exhibits multi-functionality by simultaneously acting on multiple metabolic pathways: the GLP-1 receptor agonist component stimulates glucose-dependent insulin secretion and suppresses glucagon release, while the GIPR antagonist component blocks GIP-mediated insulin secretion and fat storage. This universal approach addresses multiple metabolic disorders (type 2 diabetes, obesity, NAFLD) through a single therapeutic formulation, achieving comprehensive metabolic management without requiring multiple separate treatments.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy provides sustained benefits by reducing glucose levels, insulin resistance, body weight, and liver steatosis, while enhancing glucose tolerance and lipid profiles, offering a more comprehensive treatment approach than existing therapies.
Implementation Method 1
administering a combination of a GLP-1 receptor agonist and a GIPR antagonist, which can be administered separately or synergistically, to specifically bind to the GIPR
Implementation Method 2
a GIPR antagonist that specifically binds to a protein having an amino acid sequence having at least 90% amino acid sequence identity to an amino acid sequence of a GIPR
Data Source
AI summary
Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.